There is more for the market to discover in the IXC story

This stock has not event started to run....

https://www.livewiremarkets.com/wires/desk-note-invex-therapeutics-ixc-ixc-post-placement-indigestion-an-opportunity-mkt-cap-f-diluted-a-131-2m-1-455

Both IXC and PAR (Paradigm Biopharmaceuticals) are repurposing existing drugs, successfully completed Phase II trials, completed recent capital raises.

IXC does not have the profile of PAR which may be on the cusp of an ASX300 inclusion. It was floated out of the West, better known for resource deals, has a smaller market cap, and less liquidity than PAR. But perhaps that is the opportunity? There are a number of reasons to take a closer look at IXC....

Read the article. It's a good one.